iQure Pharma Announces Positive Completion of Phase 1 Clinical Study of iQ-007

First-in-class EAAT2 positive allosteric modulator was well tolerated in healthy volunteers, supporting progression toward Phase 2 proof-of-concept in epilepsy.

August 5, 2026 – Princeton, NJ – iQure Pharma, a clinical-stage biotech company developing first-in-class astrocyte-targeted therapies designed to restore glutamate balance in CNS disorders, today announced the completion of its Phase 1 clinical study of iQ-007, the company’s lead oral small molecule and first-in-class EAAT2 positive allosteric modulator.

The Phase 1 study enrolled 72 healthy volunteers and evaluated the safety, tolerability and pharmacokinetic profile of iQ-007. Phase 1 results supported continued clinical development, with iQ-007 being well tolerated at exposures covering the range projected to be therapeutically relevant for Phase 2.

iQ-007 is designed to enhance physiological glutamate clearance through EAAT2, the primary astrocytic transporter responsible for maintaining glutamate homeostasis in the brain. By restoring astrocyte-mediated glutamate uptake, iQure aims to address excitotoxicity, a self-amplifying process associated with neuronal overstimulation and damage across CNS disorders.

“The completion of Phase 1 is an important milestone for iQure and for the development of EAAT2 modulation as a new therapeutic approach, further positioning astrocytes as a new control point in CNS disease,” said Pawel Zolnierczyk, Co-founder and CEO of iQure Pharma. “The study outcome supports further clinical evaluation of iQ-007 as we prepare for Phase 2 proof-of-concept, as our first clinical validation path.”

“The clinical transition of iQ-007 reflects years of work around a differentiated mechanism targeting astrocyte biology rather than direct neuronal suppression,” said Henk de Wilde, CDO/COO of iQure Pharma. “These Phase 1 results provide an important foundation for the next stage of development.”